Published in Int J Cancer on December 15, 2010
Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol (2013) 1.14
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol (2013) 1.04
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer (2014) 0.90
Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol (2014) 0.86
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia (2012) 0.83
Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med (2013) 0.82
Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Dig Dis Sci (2010) 0.78
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics (Sao Paulo) (2012) 0.76
Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget (2017) 0.76
Vitamin K and hepatocellular carcinoma: The basic and clinic. World J Clin Cases (2015) 0.75
Vitamin K1 exerts antiproliferative effects and induces apoptosis in three differently graded human colon cancer cell lines. Biomed Res Int (2015) 0.75
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. Br J Radiol (2014) 0.75
Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways. PLoS One (2016) 0.75
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. Cancer Sci (2017) 0.75
Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. J Cancer (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Apoptosis: a review of programmed cell death. Toxicol Pathol (2007) 17.92
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol (2006) 2.25
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab (2009) 2.17
Programmed cell death: alive and well in the new millennium. Trends Cell Biol (2001) 1.96
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia (2008) 1.84
Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res (2000) 1.71
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene (2004) 1.67
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol (2002) 1.63
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist (2008) 1.51
Retracted Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res (2007) 1.39
Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma (2008) 1.35
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol (2009) 1.19
Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther (2007) 1.15
Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res (2009) 1.12
Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy (2008) 1.03
Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol (2007) 0.97
Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology (2004) 0.95
Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J Biol Chem (2000) 0.94
The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res (2008) 0.92
Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol (2006) 0.89
Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology (2008) 0.88
Partial purification and characterization of a hepatocyte growth factor produced by rat hepatocellular carcinoma cells. Cancer Res (1985) 0.86
Vitamin K(2) selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from geranylgeraniol. J Cancer Res Clin Oncol (2002) 0.85
Coagulation meets calcification: the vitamin K system. Int J Artif Organs (2009) 0.85
Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy (2008) 0.83
Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol (2005) 0.81
[Clinical application of vitamin K for hepatocellular carcinoma]. Clin Calcium (2007) 0.77
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer (2007) 2.64
Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol (2007) 2.49
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A (2007) 1.90
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem (2006) 1.79
Tailored navigation in colorectal cancer screening. Med Care (2008) 1.79
Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med (2004) 1.68
Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol (2002) 1.63
G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension (2009) 1.62
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol (2005) 1.58
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
Role of IL-10-Producing Regulatory B Cells in Chronic Hepatitis B Virus Infection. Dig Dis Sci (2014) 1.44
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res (2006) 1.42
Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med (2009) 1.41
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol (2005) 1.39
Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res (2005) 1.31
Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg (2009) 1.29
A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood (2011) 1.28
A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest (2011) 1.27
Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet (2003) 1.27
Functional P2Y2 nucleotide receptors mediate uridine 5'-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. Circulation (2002) 1.27
Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med (2003) 1.21
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg (2007) 1.19
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2011) 1.18
JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. J Cell Physiol (2003) 1.18
Racial differences in severe perineal lacerations after vaginal delivery. Am J Obstet Gynecol (2003) 1.17
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J (2008) 1.15
GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One (2012) 1.13
GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer (2011) 1.13
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer (2012) 1.12
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol (2011) 1.12
Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer (2003) 1.12
Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol (2010) 1.11
Selection of optimal reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics (2010) 1.11
Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK. J Biol Chem (2003) 1.11
Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg (2008) 1.08
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn (2005) 1.07
Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck (2009) 1.07
Antecedent hydrogen sulfide elicits an anti-inflammatory phenotype in postischemic murine small intestine: role of BK channels. Am J Physiol Heart Circ Physiol (2010) 1.06
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res (2010) 1.04
Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer (2013) 1.03
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther (2006) 1.02
Relative quantification based on logistic models for individual polymerase chain reactions. Stat Med (2007) 1.02
Hydrogen sulfide preconditioning or neutrophil depletion attenuates ischemia-reperfusion-induced mitochondrial dysfunction in rat small intestine. Am J Physiol Gastrointest Liver Physiol (2011) 1.01
A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes? J Gastrointest Surg (2012) 1.00
Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation (2011) 1.00
Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol Int (2007) 0.99
Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol (2002) 0.99
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther (2004) 0.99
The role of vacuolar processing enzyme (VPE) from Nicotiana benthamiana in the elicitor-triggered hypersensitive response and stomatal closure. J Exp Bot (2010) 0.98
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol (2007) 0.96
Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol (2010) 0.95
Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol (2014) 0.94
Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res (2009) 0.93
90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging (2005) 0.92
Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology (2002) 0.92
Cloning, up-regulation, and mitogenic role of porcine P2Y2 receptor in coronary artery smooth muscle cells. Mol Pharmacol (2004) 0.92
Psychometric properties of the Spence Children's Anxiety Scale (SCAS) in Mainland Chinese children and adolescents. J Anxiety Disord (2012) 0.91
Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res (2011) 0.91
Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol (2010) 0.90
Molecular staging individualizing cancer management. J Surg Oncol (2012) 0.90
Systematic prediction of human membrane receptor interactions. Proteomics (2009) 0.90
Phylogenetic analysis of hepatitis E virus isolates in southern China (1994-1998). J Clin Virol (2006) 0.90
Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Anal Biochem (2005) 0.90
Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res (2006) 0.90
Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma. J Psychosoc Oncol (2007) 0.90
Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. Biochemistry (2003) 0.89
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. J Cell Physiol (2010) 0.89
Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5. J Cell Physiol (2005) 0.89
Posttraumatic growth, immunity and survival in patients with hepatoma. Dig Dis Sci (2007) 0.88
Survival associated pathway identification with group Lp penalized global AUC maximization. Algorithms Mol Biol (2010) 0.88
HCC and its microenvironment. Hepatogastroenterology (2013) 0.88
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer Causes Control (2014) 0.87
Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK. Biochem Pharmacol (2006) 0.87
Revealing genes associated with vitellogenesis in the liver of the zebrafish (Danio rerio) by transcriptome profiling. BMC Genomics (2009) 0.87
Has the use of routine episiotomy decreased? Examination of episiotomy rates from 1983 to 2000. Obstet Gynecol (2002) 0.87
Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. Qual Life Res (2005) 0.87